Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer; N. Cook; T. Arkenau; J. Melear; C. Redfern; A. I. Spira; K. Chung; T. Haddad; S. S. Ramalingam; R. Wesolowski; E. Dean; T. Goddemeier; M. Falk; G. Shapiro

doi:10.1093/annonc/mdy292.059

Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer, N. Cook, T. Arkenau, J. Melear, C. Redfern, A. I. Spira, K. Chung, T. Haddad, S. S. Ramalingam, R. Wesolowski, E. Dean, T. Goddemeier, M. Falk, G. Shapiro

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii519
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy292.059
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy292.059

Cite this

Plummer, R., Cook, N., Arkenau, T., Melear, J., Redfern, C., Spira, A. I., Chung, K., Haddad, T., Ramalingam, S. S., Wesolowski, R., Dean, E., Goddemeier, T., Falk, M., & Shapiro, G. (2018). Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii519. https://doi.org/10.1093/annonc/mdy292.059

Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). / Plummer, R.; Cook, N.; Arkenau, T. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii519.

Research output: Contribution to journal › Article › peer-review

Plummer, R, Cook, N, Arkenau, T, Melear, J, Redfern, C, Spira, AI, Chung, K, Haddad, T, Ramalingam, SS, Wesolowski, R, Dean, E, Goddemeier, T, Falk, M & Shapiro, G 2018, 'Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii519. https://doi.org/10.1093/annonc/mdy292.059

Plummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI et al. Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii519. doi: 10.1093/annonc/mdy292.059

@article{745df019d6c24958bd38233259416613,

title = "Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)",

author = "R. Plummer and N. Cook and T. Arkenau and J. Melear and C. Redfern and Spira, {A. I.} and K. Chung and T. Haddad and Ramalingam, {S. S.} and R. Wesolowski and E. Dean and T. Goddemeier and M. Falk and G. Shapiro",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy292.059",

language = "English (US)",

volume = "29",

pages = "viii519",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

AU - Plummer, R.

AU - Cook, N.

AU - Arkenau, T.

AU - Melear, J.

AU - Redfern, C.

AU - Spira, A. I.

AU - Chung, K.

AU - Haddad, T.

AU - Ramalingam, S. S.

AU - Wesolowski, R.

AU - Dean, E.

AU - Goddemeier, T.

AU - Falk, M.

AU - Shapiro, G.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530187&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy292.059

DO - 10.1093/annonc/mdy292.059

M3 - Article

C2 - 32137346

SN - 0923-7534

VL - 29

SP - viii519

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this